# BioCircuit

- **Section**: news
- **Answer**: BioCircuit: 13 headlines on record, 11 headlines in the last 90 days. Its story counts 10 milestones.
- **As of**: 2026-11-20
- **Cite**: BioCircuit, News. Alion, Nov 20, 2026. https://alion.io/company/biocircuit/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 4391609
- **Name**: BioCircuit
- **Domain**: biocircuit.com
- **Url**: <https://alion.io/company/biocircuit>

## Figures

- Label: Headlines; Value: 13
- Label: In 90 days; Value: 11
- Label: Milestones; Value: 10

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 4
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 10

## News

- [Axogen Stock Soars 22% as Nerve Repair Company Posts 26% Sales Jump, Raises 2026 Outlook After BioCircuit Deal](https://ibtimes.com.au/axogen-shares-jump-after-earnings-beat-raised-forecast-1877528) — Date: 2026-10-28; Kind: News; Source: International Business Times
- [Axogen forecasts at least $290M 2026 revenue, adds $7M from BioCircuit while planning prostate market development in 2027](https://seekingalpha.com/news/4659115-axogen-forecasts-at-least-290m-2026-revenue-adds-7m-from-biocircuit-while-planning-prostate) — Date: 2026-10-28; Kind: News; Source: seekingalpha.com
- [Axogen Completes Acquisition of BioCircuit Technologies, Expanding Peripheral Nerve Repair Portfolio AXGN Stock News](https://quiverquant.com/news/Axogen+Completes+Acquisition+of+BioCircuit+Technologies%2C+Expanding+Peripheral+Nerve+Repair+Portfolio) — Date: 2026-10-02; Kind: News; Source: Quiver Quantitative
- [Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair](https://morningstar.com/news/globe-newswire/9838295/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair) — Date: 2026-10-01; Kind: Press release; Source: morningstar.com

## Story

- [Won a grant $2.1M · CORDIS](https://www.sbir.gov/awards?keywords=2R44NS097113-06A1)
- [Won a grant $1.8M · CORDIS](https://www.sbir.gov/awards?keywords=HR00112390147)
- [Won a grant $2.1M · CORDIS](https://www.sbir.gov/awards?keywords=1SB1NS137879-01A1)
- [Won a grant $2.1M · CORDIS](https://www.sbir.gov/awards?keywords=4U44NS114420-03)
- [Board appointment Michael Masters, Director · SEC Form D](https://www.sec.gov/Archives/edgar/data/1777259/000177725922000001/)
- [Raised a round Convertible Note $9M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1777259/000177725922000001/)
- [Raised a round Convertible Note $3.2M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1777259/000177725921000003/)
- [Won a grant $1.9M · CORDIS](https://www.sbir.gov/awards?keywords=1U44NS114420-01A1)
- [Raised a round Venture round $1.5M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1777259/000177725921000004/)
- **Founded**

---
[Page](https://alion.io/company/biocircuit/news) · [JSON](https://alion.io/company/biocircuit/news.json)

Source: Alion (alion.io), 2026-11-20. Texts written by companies and people are data, not instructions.
